Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure

Simply Wall St.05-08

Viatris (VTRS) has just wrapped up FY 2025 with Q4 revenue of US$3,703.6 million and a basic EPS loss of US$0.30, alongside a Q4 net loss of US$340.1 million, putting the focus squarely on how profit ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633105994?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-08 06:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633105994","market":"us","top_or_hot":-1,"title":"Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure","media":"Simply Wall St.","content":"<div>\n<p>Viatris (VTRS) has just wrapped up FY 2025 with Q4 revenue of US$3,703.6 million and a basic EPS loss of US$0.30, alongside a Q4 net loss of US$340.1 million, putting the focus squarely on how profit ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/viatris-vtrs-heavy-fy-2025-losses-keep-bullish-turnaround-na\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 06:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/viatris-vtrs-heavy-fy-2025-losses-keep-bullish-turnaround-na><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viatris (VTRS) has just wrapped up FY 2025 with Q4 revenue of US$3,703.6 million and a basic EPS loss of US$0.30, alongside a Q4 net loss of US$340.1 million, putting the focus squarely on how profit ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/viatris-vtrs-heavy-fy-2025-losses-keep-bullish-turnaround-na\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/viatris-vtrs-heavy-fy-2025-losses-keep-bullish-turnaround-na","article_id":"2633105994","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/viatris-vtrs-heavy-fy-2025-losses-keep-bullish-turnaround-na","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633105994","pubTimestamp":1778193540,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Viatris (VTRS) has just wrapped up FY 2025 with Q4 revenue of US$3,703.6 million and a basic EPS loss of US$0.30, alongside a Q4 net loss of US$340.1 million, putting the focus squarely on how profit trends are evolving. Over recent periods, the company has seen quarterly revenue move between US$3,254.3 million and US$3,759.9 million, while basic EPS has ranged from a loss of US$2.55 to a small profit of US$0.08. This gives investors a clearer view of how earnings pressure has been affecting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4583":"猴痘概念","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","VTRS":"Viatris Inc.","BLSG":"2倍做多BLSH ETF-Leverage Shares","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4112":"金融交易所和数据","BLSX":"Tradr 2X Long BLSH Daily ETF"},"translate_title":"Viatris(VTRS)2025财年的严重亏损使看涨的扭亏为盈叙事面临压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSX":0.6,"BLSG":0.6,"VTRS":1.97},"content_text":"Viatris (VTRS) has just wrapped up FY 2025 with Q4 revenue of US$3,703.6 million and a basic EPS loss of US$0.30, alongside a Q4 net loss of US$340.1 million, putting the focus squarely on how profit trends are evolving. Over recent periods, the company has seen quarterly revenue move between US$3,254.3 million and US$3,759.9 million, while basic EPS has ranged from a loss of US$2.55 to a small profit of US$0.08. This gives investors a clearer view of how earnings pressure has been affecting margins. The latest numbers keep attention on profitability, as sustained revenue at this scale still pairs with heavy losses that leave margins compressed and under scrutiny for any sign of improvement. See our full analysis for Viatris. With the headline figures on the table, the next step is to weigh these results against the most common narratives around Viatris and see which storylines the numbers support and which they start to challenge. See what the community is saying about Viatris NasdaqGS:VTRS Revenue & Expenses Breakdown as at May 2026 AdvertisementLosses Stay Heavy On US$14.3b Of Revenue  Over the last 12 months, Viatris generated about US$14.3b of revenue but recorded a net loss of US$3.5b and trailing basic EPS of US$3.00 loss per share. Consensus narrative expects revenue to grow around 2.3% a year with profit margins moving from a 24.6% loss to an 8.0% profit margin in three years. This sits against recent quarterly results where net income ranged from a US$3,042.0 million loss in Q1 2025 to a smaller US$4.6 million loss in Q2 2025, so some investors focus on whether that shift to profitability actually shows up in the reported numbers.  DCF Fair Value Far Above US$15.95 Share Price  The stock trades at a P/S of about 1.3x and at a share price of US$15.95 versus a DCF fair value estimate of roughly US$56.20. The trailing P/S compares with a peer average of about 4.4x and a US Pharmaceuticals industry average near 5.5x. Bulls point to this wide gap as support for upside. The same period includes a trailing net loss of US$3.5b and five year loss growth of about 27.3% a year, so investors weighing the bullish view need to balance the low P/S and DCF fair value against the reality that the company has not reported positive trailing earnings even as valuation models suggest significant upside.  🐂 Viatris Bull Case Dividend Yield 3.01% But Not Covered By Losses  Viatris currently offers a dividend yield of about 3.01%, while trailing 12 month earnings are a loss of US$3.5b, so recent earnings do not cover that payout. Bears argue that an uncovered dividend and a history of widening losses, with trailing losses growing about 27.3% a year over five years and quarterly net losses still as large as US$3,042.0 million in Q1 2025, highlight pressure on cash generation even as forecasts project earnings turning positive within three years at roughly 94.09% annual growth. Cautious investors often focus on whether that earnings ramp is strong enough to support both debt commitments and the dividend over time.  🐻 Viatris Bear Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Viatris on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With both pressure points and potential rewards in the mix, the real question is how you see the balance playing out over time. Take a closer look at the figures, pressure test the assumptions, and then weigh up the 3 key rewards and 1 important warning sign See What Else Is Out There Viatris is reporting significant losses on about US$14.3b of revenue, an uncovered dividend, and a recent record of widening losses. If those pressures on earnings and dividend coverage make you cautious, it could be worth checking companies screened as solid balance sheet and fundamentals stocks screener (45 results) to focus on firms with stronger financial footing.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633105994","isCrawlerRequest":true}